A study reporting on DiscGenics’ cell therapy phase 1 and 2 study has been selected as one of three of the best and most influential articles published in the International Journal of Spine Surgery in 2024.
Here are four things to know, according to an April 9 news release from DiscGenics:
- The report reviewed results from the combined phase 1 and 2 clinical study of allogeneic disc progenitor cell therapy, or rebonuputemcel, for painful lumbar degenerative disc disease.
- The study found that a single intradiscal injection of high-dose IDCT safely increases disc volume and produces statistically significant, clinically meaningful improvements in back pain, disability and quality of life.
- Matthew Gornet, MD, a spine surgeon at The Orthopedic Center in St. Louis, is lead author of the article.
- DiscGenics is preparing to initiate phase 3 of the clinical study for injectable disc cell therapy in the U.S.
Read the full research article here.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.